http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-051095-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f1a30682c7f24ace5f2b16c6be633b6 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| filingDate | 2005-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2006-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-051095-A1 |
| titleOfInvention | HETEROCICLIC DERIVATIVES AND ITS USE AS INHIBITORS OF ESTEAROIL-COA DESATURASA |
| abstract | Methods for treating a disease or condition mediated by SCD in a mammal, preferably a human being. Pharmaceutical compositions comprising the compounds of formula (1) are also disclosed. Claim 10: A compound characterized in that it responds to formula (1) wherein: x and y are each independently 0, 1, 2 or 3; G is -N = or -C (R4) =; J and K are each independently N or C (R10); L and M are each independently -N = or -C (R4) =, with the proviso that L and M cannot be both -C (R4) = when G is -C (R4) = and with the except that L and M cannot be both -N = when G is -N =; V is a direct link, -N (R1) -, -N (R1) C (O) -, -O-, -C (O) -, -C (O) O-, -C (S) -, -C (O) N (R1) -, -S (O) p- (where p is 0, 1 or 2) or -S (O) pN (R1) - (where p is 1 or 2); W is a direct link, -N (R1) C (O) -, -C (O) N (R1) -, -OC (O) N (R1) -, -N (R1) C (O) N ( R1) -, -O-, -N (R1) -, -S (O) t- (where t is 0, 1 or 2), -N (R1) S (O) p- (where p is 1 or 2), -S (O) pN (R1) - (where p is 1 or 2), -C (O) -, - OS (O) 2N (R1) -, -OC (O) -, -C ( O) O-, or -N (R1) C (O) -O-2; each R1 is independently selected from the group consisting of H, C1-12 alkyl, C2-12 hydroxyalkyl, C4-12 cycloalkylalkyl and C7-19 aralkyl; R2 is selected from the group consisting of C1-12 alkyl, C2-12 alkenyl, C2-12 hydroxyalkyl, C2-12 hydroxyalkenyl, C2-12 alkoxyalkyl, C3-12 cycloalkyl, C4-12 cycloalkylalkyl, aryl, C7-19 aralkyl, C3 -12 heterocyclyl, C3-12 heterocyclylalkyl, C1-12 heteroaryl, and C3-12 heteroarylalkyl; or R2 is a multiple ring structure having between 2 and 4 rings where the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and, where some or all of the rings may be fused together, R3 is Select from the group consisting of H, C1-12 alkyl, C2-12 alkenyl, C2-12 hydroxyalkyl, C2-12 hydroxyalkenyl, C2-12 alkoxyalkyl, C3-12 cycloalkyl, C4-12 cycloalkylalkyl, aryl, C7-19 aralkyl, C3 -12 heterocyclyl, C3-12 heterocyclylalkyl, C1-12 heteroaryl, and C3-12 heteroarylalkyl; or R3 is a multiple ring structure having between 2 and 4 rings where the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and, where some or all of the rings may be fused together; R4 is independently selected from H, F, Cl, C1-12 alkyl, C1-12 alkoxy, haloalkyl, cyano, nitro or -N (R9) 2; or two contiguous R4 groups, together with the C atoms to which they are attached, can form an aryl, heteroaryl or heterocyclyl ring system; R5, R5a, R6, R6a, R7, R7a, R8 and R8a are each independently selected from H or C1-3 alkyl; or R5 and R5a together, R6 and R6a together, or R7 and R7a together, or R8 and R8a together constitute an oxo group, with the proviso that when V is -C (O) -, R6 and R6a together or R8 and R8a together they do not form an oxo group, while the remaining R5, R5a, R6, R6a, R7, R7a, R8 and R8a are each independently selected from H or C1-3 alkyl; or one of R5, R5a, R6 and R6a together with one of R7, R7a, R8 and R8a forms a direct bond or an alkylene bridge, while the remaining R5, R5a, R6, R6a, R7, R7a, R8 and R8a are selected each independently between H or C1-3 alkyl; each R9 is independently selected from H or C1-6 alkyl; and R10 is independently selected from H, F, Cl, C1-12 alkyl or C1-12 alkoxy; in the form of one its stereoisomers, enantiomers or tautomers, in the form of a mixture of stereoisomers, in the form of salt acceptable for pharmaceutical use, or as prodrug thereof. |
| priorityDate | 2004-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 23.